Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

BioNewsCast Press Release Distribution Service

Bioinformatics Market Potential

Vaccine Research & Development 2009

Practical Guide to Finding Partners in Pharma & Biotech, 2nd edition

Royalty Financing Agreements in Pharma, Biotech and Diagnostics

New Products

Advanced Wound Management Pipeline Technology and Market Forecasts to 2015

Artificial Disc Replacement Pipeline Technology and Market Forecasts to 2015

Brazil Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015

Brazil Orthopedic Devices Market Analysis and Forecasts to 2015

Canada Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015

Canada Diabetes Care Devices Market Analysis and Forecasts to 2015

Canada Medical Equipment Market Analysis and Forecasts to 2015

Cardiac Assist Devices Pipeline Technology and Market Forecasts to 2015

China Medical Equipment Market Analysis and Forecasts to 2015

Chronic Diseases on the Rise: Personal Health Systems to Play a Key Role in Disease Management

BioPortfolio | La Merie | Competitor Analysis: Janus Kinase (JAK) Inhibitors

Competitor Analysis: Janus Kinase (JAK) Inhibitors

The present Competitive Intelligence Report about new developments in the pipeline of inhibitors of the janus-associated kinase (JAK) provides a competitor evaluation in the field of R&D projects from preclinical stages up to advanced clinical phases of JAK Inhibitors as of December 2008.

As cytokines play pivotal roles in immunity and inflammation, targeting of cytokines and their receptors represents an effective means of treating such diseases. Janus kinases (JAK) are a small family of receptor-associated kinases, that together with signal transducers and activators of transcription (STAT), provide a rapid signalling pathway for cytokines. Four JAKs have been identified: JAK1, JAK2, JAK3 and tyrosine kinase 2 (Tyk2). JAK3 has attracted much attention as an anti-inflammatory drug target because of its restricted hematopoietic tissue expression and because of its specific association with the common gamma chain of the interleukin-2 (IL-2) receptor which is shared by the receptors for IL-4, IL-7, IL-9, IL-15 and IL-21. Quite a number of companies are developing selective JAK3 inhibitors as JAK3 appears not to have functions outside of hematopoetic cells. Pfizer leads the field with evaluation of JAK3 inhibition in a number of inflammatory diseases including rheumatoid arthritis, asthma, ulcerative colitis, Crohn’s disease, psoriasis and prevention of transplant rejection. Results from the first phase II study of Pfizer’s JAK3 inhibitor revealed the best reported results so far for a small molecule tested in rheumatoid arthritis. JAK2 gain-of-function mutations (JAK2V617F) underlie a subset of disorders collectively referred to as myeloproliferative disorders. The most advanced JAK2 inhibitors are also being evaluated in phase II trials for myelofibrosis, polycythemia vera and essential thrombocythemia.

The report includes a compilation of current active projects in research and development of selective and multi-kinase inhibitors incl. JAK-2 and JAK-3 inhibitors, for the treatment of myelofibrosis, polycythemia vera, psoriasis, rheumatoid arthritis and other inflammatory diseases. In addition, the report lists company-specific pipelines of JAK inhibitors. Competitor projects are listed in a tabular format providing Information on:

* Drug Codes,

* Target / Mechanism of Action,

* Class of Compound,

* Company,

* Product Category,

* Indication,

* R&D Stage and

* additional comments with a hyperlink leading to the source of information.

Index

* JAK3 Inhibitors

* JAK1&2 Inhibitors

* JAK2 Inhibitors

* Multi-Kinase Inhibitors incl. JAK inhibition

* Corporate JAK Inhibitor R&D Pipelines

* About La Merie

Corporate JAK Inhibitor R&D Pipelines

* Astellas Pharma

* Astex Therapeutics

* AstraZeneca

* Cephalon

* Cytopia

* Eli Lilly (SGX Pharmaceuticals)

* Exelixis

* Incyte Pharmaceuticals

* Johnson & Johnson

* Ligand Pharmaceuticals (Pharmacopeia)

* Merck Serono

* Novartis

* Nova Decision

* Palau Pharma

* Pfizer

* Portola Pharmaceuticals

* Rigel Pharmaceuticals

* S*Bio

* Sai Advantium

* SuperGen

* TargeGen

* Vertex Pharmaceuticals

* Wyeth

About Competitor Analysis Series

The Competitor Analysis Series delivers NO-FRILLS , but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

Publisher: La Merie

Product Line: Competitor Analysis

Pages: 27

Release Date: December of 2008

Format: PDF

Product Code: LMCA0101

Price

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions